Postes, as it stands right now I have to agree with your assessment. What I believe ALM is postulating is that the generics are betting/guessing/hoping that somehow the U.S. medical establishment comes to their senses and sees Vascepa for the great advancement in CVD care that it is.
One would think that if they were practicing medicine correctly (what is the point of clinical trials, and peer reviewed published papers) that scripts for Vascepa would zoom up. However, almost 2 years after R-I we do not see strong evidence of that.
It seems that nowadays, advertising is necessary to promote and increase sales. In Europe with no advertising I assume there is still needed promotion to physicians.
News 
Market Data 
Discover 
